CAJ | 학술논문

目的比较纯化的CD34+细胞与未经筛选的单个核细胞(uMNCs)作为种子细胞在小口径组织工程血管早期的抗凝作用.方法 uMNCs与CD34+细胞分离自犬骨髓,将两种细胞分别在体外培养、传代,内皮细胞生长因子诱导分化,体外血小板黏附实验检测细胞的体外抗血小板黏附功能.将等量自体上述两种细胞分别种植在小口径人造血管腔内表面并替代一段颈动脉.分别在24h、72 h、1周后取出移植血管行苏木素-伊红(HE)染色和扫描电镜检查.结果体外血小板黏附实验显示CD34+细胞抗血小板聚集作用显著高于uMNCs.植入体内后,移植uMNCs血管腔表面比种植CD3+细胞的有更多的血小板黏附和血栓形成.24 h、1周后CD34+细胞组血栓面积与移植的血管腔表面积之比小于uMNCs组,差异有统计学意义(P＜0.05).结论 CD34+作为种子细胞种植小口径人工血管后比未经筛选的uMNCs具有更好的早期抗血栓形成功能.
목적 비교순화적CD34+세포여미경사선적단개핵세포(uMNCs)작위충자세포재소구경조직공정혈관조기적항응작용.방법 uMNCs여CD34+세포분리자견골수,장량충세포분별재체외배양、전대,내피세포생장인자유도분화,체외혈소판점부실험검측세포적체외항혈소판점부공능.장등량자체상술량충세포분별충식재소구경인조혈관강내표면병체대일단경동맥.분별재24h、72 h、1주후취출이식혈관행소목소-이홍(HE)염색화소묘전경검사.결과 체외혈소판점부실험현시CD34+세포항혈소판취집작용현저고우uMNCs.식입체내후,이식uMNCs혈관강표면비충식CD3+세포적유경다적혈소판점부화혈전형성.24 h、1주후CD34+세포조혈전면적여이식적혈관강표면적지비소우uMNCs조,차이유통계학의의(P＜0.05).결론 CD34+작위충자세포충식소구경인공혈관후비미경사선적uMNCs구유경호적조기항혈전형성공능.
Objective To compare the antithrombogenic property of purified CD34 + cells with that of unfractioned mononuclear cells (uMNCs) after seeding on the small caliber man-made grafts. Methods uMNCs and CD34 + cells were isolated from the canine bone marrow. Platelet adhesion assay was performed to determine antiplatelet adhesion property of the cells in vitro. Equal number of both cells were seeded onto the luminal surface of small caliber man-made grafts and implanted to replace a segment of common carotid artery. At time intervals of 24 h, 72 h, and 1 week, the grafts were retreived, HE staining and scanning election microscopy (SEM) exam were performed. Results Platelet adhesion assay indicated that there was more significant platelet adhesion on uMNCs than that on CD34 + cells. SEM revealed that there was more significant platelet adhesion and thrombus formation on the luminal surface of the grafts seeded with uMNCs than those seeded with CD34 + cells 24 h after implantation. The ratio of thrombi area to the luminal surface area of grafts in CD34 + cells group at 24 h and 1 week was statistically lower than that of the uMNCs group (P ＜0. 05). Conclusion CD34 + cells exhibit better antithrombogenic ability after seeding onto the small caliber vessel grafts as compared with uMNCs. CD34 + cells may be preferable cell source for better improve the thromboresistance and patency of small caliber man-made vessel grafts for their future clinical application.